Fiduciary Trust Co Cuts Stake in Pfizer Inc. (NYSE:PFE)

Fiduciary Trust Co trimmed its stake in Pfizer Inc. (NYSE:PFE) by 9.2% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 277,985 shares of the biopharmaceutical company’s stock after selling 28,265 shares during the quarter. Fiduciary Trust Co’s holdings in Pfizer were worth $7,375,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. First International Bank & Trust acquired a new stake in Pfizer during the fourth quarter worth about $240,000. ORG Partners LLC grew its holdings in shares of Pfizer by 6.2% during the 4th quarter. ORG Partners LLC now owns 50,879 shares of the biopharmaceutical company’s stock worth $1,351,000 after purchasing an additional 2,967 shares during the period. ST Germain D J Co. Inc. increased its position in Pfizer by 17.5% during the 4th quarter. ST Germain D J Co. Inc. now owns 30,269 shares of the biopharmaceutical company’s stock worth $803,000 after purchasing an additional 4,515 shares in the last quarter. A. D. Beadell Investment Counsel Inc. raised its holdings in Pfizer by 7.7% in the fourth quarter. A. D. Beadell Investment Counsel Inc. now owns 47,211 shares of the biopharmaceutical company’s stock valued at $1,252,000 after buying an additional 3,375 shares during the period. Finally, Hilltop National Bank lifted its position in Pfizer by 8.2% during the fourth quarter. Hilltop National Bank now owns 19,077 shares of the biopharmaceutical company’s stock valued at $506,000 after buying an additional 1,450 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of PFE opened at $22.28 on Friday. The firm has a market cap of $126.36 billion, a price-to-earnings ratio of 15.80, a PEG ratio of 0.64 and a beta of 0.58. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The business’s 50 day moving average is $24.02 and its two-hundred day moving average is $25.56. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $31.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $13.72 billion for the quarter, compared to analysts’ expectations of $14.43 billion. During the same period in the prior year, the company posted $0.82 earnings per share. The firm’s quarterly revenue was down 7.8% on a year-over-year basis. Analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, May 9th. This represents a $1.72 annualized dividend and a dividend yield of 7.72%. Pfizer’s payout ratio is 124.64%.

Wall Street Analysts Forecast Growth

PFE has been the subject of several recent research reports. Guggenheim reissued a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $25.00 price target (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Citigroup restated a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. Cantor Fitzgerald started coverage on Pfizer in a research note on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 target price for the company. Finally, Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a report on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have given a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, Pfizer has a consensus rating of “Moderate Buy” and a consensus target price of $29.17.

Insider Buying and Selling

In other news, Director Ronald E. Blaylock bought 19,457 shares of Pfizer stock in a transaction on Thursday, February 13th. The shares were bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.06% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.